This gliptin-induced inhibition of DPP-4 activity led to a rise in systemic and brain GLP-1 and GIP levels in rats [42], and supports the prospective repurposing of either gliptin as a potential PD treatment. The gene discussed is GLP1R; the disease is Parkinson disease.